Chronic Kidney Disease Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Product Type, By End User, By Region & Competition, 2020-2030F

Description

Global Chronic Kidney Disease Treatment Market was valued at USD 35.40 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 4.70% through 2030. The Global Chronic Kidney Disease (CKD) Treatment Market is a critical component of the broader healthcare industry, encompassing a wide range of medical interventions, therapies, and medications aimed at managing and improving the quality of life for individuals affected by CKD. CKD is a progressive and often asymptomatic condition that can lead to kidney failure if left untreated. As such, the CKD Treatment Market plays a pivotal role in addressing this global health concern.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 35.40 Billion
Market Size 2030	USD 46.74 Billion
CAGR 2025-2030	4.70%
Fastest Growing Segment	Diagnosis Segment
Largest Market	North America

Key Market Drivers

Rising Prevalence of Chronic Kidney Disease (CKD) and Related Comorbidities

The increasing global prevalence of Chronic Kidney Disease (CKD) is a fundamental driver of the Global CKD Treatment Market, as it directly fuels demand for pharmaceuticals, dialysis services, renal replacement therapies, and specialized healthcare services. This rising disease burden is largely attributed to several interconnected factors, including aging populations, lifestyle-related disorders, and genetic predispositions. Chronic Kidney Disease is a progressive and irreversible condition that affects millions worldwide. The 2023 ISN-GKHA multinational study on the global burden of kidney disease reports that approximately 850 million people worldwide are affected by Chronic Kidney Disease (CKD). The findings highlight that CKD impacts individuals across all age groups and racial backgrounds, with a disproportionately higher prevalence among economically disadvantaged populations. These insights emphasize the urgent need for targeted healthcare policies, improved access to early diagnosis, and expanded treatment infrastructure, particularly in high-risk and underserved communities, with a significant portion of cases remaining undiagnosed until the later stages. This expanding patient population is a major catalyst for the growth of the CKD treatment market. Improved screening programs and awareness campaigns are leading to earlier diagnoses, increasing demand for medications and lifestyle management interventions. Among patients without proteinuria data, the CKD diagnosis rate was 5.9%, with a significantly lower rate of 2.9% in stage G2. In contrast, for patients with quantitative proteinuria test results, the diagnosis rates were 43.5% overall and 31.3% in stage G2. These findings underscore the critical role of quantitative proteinuria testing in early CKD detection, highlighting a significant gap in diagnosis rates when such data is unavailable. This reinforces the need for wider adoption of advanced diagnostic protocols to improve CKD identification and clinical decision-making.

Key Market Challenges

Economic Barriers and Healthcare Disparities

One of the primary challenges is the economic disparity that exists globally. Access to advanced CKD treatments and medications often requires significant financial resources. High healthcare costs, including expenses related to dialysis, transplantation, and specialized medications, can be prohibitive for individuals with limited financial means.

In many regions, healthcare coverage and insurance options may not adequately address CKD treatment costs. Patients without comprehensive insurance may face difficulties in accessing essential treatments, which can lead to delayed or suboptimal care. Vulnerable populations, such as low-income individuals and underserved communities, are disproportionately affected by economic barriers. This can result in delayed CKD diagnosis, limited access to specialized care, and poorer outcomes.

Key Market Trends

Personalized Medicine and Precision Care

Personalized medicine is gaining prominence in the CKD treatment market. Healthcare providers are increasingly customizing treatment plans to meet the specific needs of individual CKD patients. This approach takes into account factors such as the patient's stage of CKD, comorbidities, genetic factors, and response to previous treatments.

Biomarker research plays a crucial role in personalizing CKD treatment. Biomarkers, such as specific proteins or genetic markers, are used to predict disease progression and treatment efficacy. This trend enables healthcare professionals to make more informed decisions about treatment strategies, including medication selection and dosing. Advances in genomics are revolutionizing CKD care. Genetic testing can identify genetic mutations or predispositions that influence CKD risk and progression. This information allows for the development of targeted therapies and interventions, with the potential to slow or halt disease progression in individuals with specific genetic profiles.

Key Market Players

AbbVie Inc.
Amgen Inc.
Bayer AG
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline PLC
Merck & Co. Inc.
Pfizer Inc.
Sysmex Corporation
Teva Pharmaceutical Industries Ltd

Report Scope:

In this report, the Global Chronic Kidney Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Chronic Kidney Disease Treatment Market, By Product Type:

Diagnosis
Treatment
Dialysis
Others

Chronic Kidney Disease Treatment Market, By End User:

Hospitals
Diagnostic Laboratories
Others

Chronic Kidney Disease Treatment Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chronic Kidney Disease Treatment Market.

Available Customizations:

Global Chronic Kidney Disease Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chronic Kidney Disease Treatment Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Product Type (Diagnosis, Treatment, Dialysis, Others)
- 5.2.2. By End User (Hospital, Diagnostic Laboratories, Other)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Chronic Kidney Disease Treatment Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Product Type
- 6.2.2. By End User
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Chronic Kidney Disease Treatment Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Product Type
    - 6.3.1.2.2. By End User
- 6.3.2. Canada Chronic Kidney Disease Treatment Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Product Type
    - 6.3.2.2.2. By End User
- 6.3.3. Mexico Chronic Kidney Disease Treatment Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Product Type
    - 6.3.3.2.2. By End User

7. Europe Chronic Kidney Disease Treatment Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Product Type
- 7.2.2. By End User
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Chronic Kidney Disease Treatment Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Product Type
    - 7.3.1.2.2. By End User
- 7.3.2. United Kingdom Chronic Kidney Disease Treatment Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Product Type
    - 7.3.2.2.2. By End User
- 7.3.3. Italy Chronic Kidney Disease Treatment Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Product Type
    - 7.3.3.2.2. By End User
- 7.3.4. France Chronic Kidney Disease Treatment Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Product Type
    - 7.3.4.2.2. By End User
- 7.3.5. Spain Chronic Kidney Disease Treatment Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Product Type
    - 7.3.5.2.2. By End User

8. Asia-Pacific Chronic Kidney Disease Treatment Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Product Type
- 8.2.2. By End User
8.2.3 By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Chronic Kidney Disease Treatment Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Product Type
    - 8.3.1.2.2. By End User
- 8.3.2. India Chronic Kidney Disease Treatment Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Product Type
    - 8.3.2.2.2. By End User
- 8.3.3. Japan Chronic Kidney Disease Treatment Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Product Type
    - 8.3.3.2.2. By End User
- 8.3.4. South Korea Chronic Kidney Disease Treatment Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Product Type
    - 8.3.4.2.2. By End User
- 8.3.5. Australia Chronic Kidney Disease Treatment Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Product Type
    - 8.3.5.2.2. By End User

9. South America Chronic Kidney Disease Treatment Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Product Type
- 9.2.2. By End User
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Chronic Kidney Disease Treatment Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Product Type
    - 9.3.1.2.2. By End User
- 9.3.2. Argentina Chronic Kidney Disease Treatment Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Product Type
    - 9.3.2.2.2. By End User
- 9.3.3. Colombia Chronic Kidney Disease Treatment Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Product Type
    - 9.3.3.2.2. By End User

10. Middle East and Africa Chronic Kidney Disease Treatment Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Product Type
- 10.2.2. By End User
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Chronic Kidney Disease Treatment Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Product Type
    - 10.3.1.2.2. By End User
- 10.3.2. Saudi Arabia Chronic Kidney Disease Treatment Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Product Type
    - 10.3.2.2.2. By End User
- 10.3.3. UAE Chronic Kidney Disease Treatment Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Product Type
    - 10.3.3.2.2. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Chronic Kidney Disease Treatment Market: SWOT Analysis

14. Competitive Landscape

14.1. AbbVie Inc.
- 14.1.1. Business Overview
- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
14.2. Amgen Inc.
14.3. Bayer AG
14.4. Bristol-Myers Squibb Company
14.5. F. Hoffmann-La Roche Ltd
14.6. GlaxoSmithKline PLC
14.7. Merck & Co. Inc.
14.8. Pfizer Inc.
14.9. Sysmex Corporation
14.10. Teva Pharmaceutical Industries Ltd.